Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Breast Cancer Research

Volumn 9, Issue 1, 2007, Pages

  Wegman, Pia ^a   Elingarami, Sauli ^a   Carstensen, John ^a   Stål, Olle ^a   Nordenskjöld, Bo ^a   Wingren, Sten ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE; PROTEIN UGT2B15; SULFOTRANSFERASE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ARYL SULFOTRANSFERASE; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; SULT1A1 PROTEIN, HUMAN; UDP GLUCURONOSYLTRANSFERASE 2B15, HUMAN; UDP-GLUCURONOSYLTRANSFERASE 2B15, HUMAN;

ADULT; AGED; ALLELE; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE-FREE SURVIVAL; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 34248208754     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1640     Document Type: Article

References (37)

1. Early Breast Cancer Trialist's Collaborative Group (EBCTCG) Tamoxifen for early breast cancer: An overview of randomised trials Lancet 1998, 351:1451-1467 10.1016/S0140-6736(97)11423-4 9605801
2. Stearns V Johnson M Rae JM Morocho A Novielli A Bhargava P Hayes DF Desta Z Flockhart DA Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 2003, 95:1758-1764 14652237
3. Johnson MD Zuo H Lee K-H Trebley JP Rae JM Weatherman RV Desta Z Flockhart DA Skaar TC Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 2004, 85:151-159 10.1023/ B:BREA.0000025406.31193.e8 15111773
4. Lim YC Desta Z Flockhart DA Skaar T Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol 2005, 55:471-478 10.1007/s00280-004-0926-7 15685451
5. MacCallum J Cummings J Dixon JM Miller WR Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours Br J Cancer 2000, 82:1629-1635 10.1054/bjoc.2000.1120 10817496
6. Kisanga ER Gjerde J Guerrieri-Gonzaga A Pigatto F Pesci-Feltri A Robertson C Serrano D Pelosi G Decensi A Lien EA Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial Clin Cancer Res 2004, 10:2336-2343 10.1158/1078-0432.CCR-03-0538 15073109
7. Fabian C Tilzer L Sternson L Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: Correlation with blood levels in patients with metastatic breast cancer Biopharm Drug Dispos 1981, 2:381-390 10.1002/bdd.2510020407 7317574
8. Coezy E Borgna J-L Rochefort H Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res 1982, 42:317-323 7053859
9. Murphy CS Langan-Fahey SM McCague R Jordan VC Structure function relationship of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro Mol Pharmacol 1990, 38:737-743 2233701
10. Jacolot F Simon I Dreano Y Beaune P Riche C Berthou F Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes Biochem Pharmacol 1991, 41:1911-1919 10.1016/0006-2952(91)90131-N 2039544
11. Crewe HK Ellis SW Lennard MS Tucker GT Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem Pharmacol 1997, 53:171-178 10.1016/ S0006-2952(96)00650-8 9037249
12. Dehal SS Kupfer D CYP2D6 catalyses tamoxifen 4-hydroxylation in human liver Cancer Res 1997, 57:3402-3406 9270005
13. Jordan VC Haldemann B Allen KE Geometric isomers of substituted triphenylethylenes and antiestrogen action Endocrinology 1981, 108:1353-1361 6781873
14. Katzenellenbogen BS Norman MJ Eckert RL Peltz SW Mangel WF Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells Cancer Res 1984, 44:112-119 6537799
15. Malet C Spritzer P Cumins C Guillaumin D Mauvais-Jarvis P Kuttenn F Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects on normal human breast epithelial (HBE) cells in culture J Steroid Biochem Mol Biol 2002, 82:289-296 10.1016/S0960-0760(02)00226-1 12589935
16. Osborne CK Wiebe VJ McGuire WL Ciocca DR DeGregorio MW Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients J Clin Oncol 1992, 10:304-310 1732430
17. Nishiyama T Ogura K Nakano H Ohnuma T Kaku T Hiratsuka A Muro K Watabe T Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases Biochem Pharmacol 2002, 63:1817-1830 10.1016/S0006-2952(02)00994-2 12034366
18. Kuehl P Zhang J Lin Y Lamba J Assem M Shuetz J Watkins PB Daly A Wrighton SA Hall SD Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 2001, 27:383-391 10.1038/86882 11279519
19. Hustert E Haberl M Burk O Wolbold R He YQ Klein K Nuessler AC Neuhaus P Klattig J Eiselt R The genetic determinants of CYP3A5 polymorphism Pharmacogenetics 2001, 11:773-778 10.1097/00008571-200112000-00005 11740341
20. Lamba JK Lin YS Schuetz EG Thummel KE Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 2002, 54:1271-1294 10.1016/S0169-409X(02)00066-2 12406645
21. Hanioka N Kimura S Meyer UA Gonzalez FJ The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934 - A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site Am J Hum Genet 1990, 47:994-1001 1683916 1978565
22. Raftogianis RB Wood TC Otterness DM Van Loon JA Weinshilboum RM Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype Biochem Biophys Res Commun 1997, 239:298-304 10.1006/bbrc.1997.7466 9345314
23. Iida A Saito S Sekine A Mishima C Kitamura Y Kondo K Harigae S Osawa S Nakamura Y Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8 J Hum Genet 2002, 47:505-510 10.1007/s100380200075 12376738
24. Lévesque E Beaulieu M Green MD Tephly TR Bélanger A Hum DW Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene Pharmacogenetics 1997, 7:317-325 10.1097/00008571-199708000-00007 9295060
25. Wegman P Vainikka L Stål O Nordenskjöld B Skoog L Rutqvist LE Wingren S Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 2005, 7:R284-R290 1143572 15987423 10.1186/bcr993
26. Coughtrie MW Gilissen RA Shek B Strange RC Fryer AA Jones PW Bamber DE Phenol sulphotransferase SULT1A1 polymorphism: Molecular diagnosis and allele frequencies in Caucasian and African populations Biochem J 1999, 337:45-49 1219934 9854023 10.1042/0264-6021:3370045
27. Nowell SA Ahn J Rae JM Scheys JO Trovato A Sweeney C MacLeod SL Kadlubar FF Ambrosone CB Associtation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 2005, 91:249-258 10.1007/s10549-004-7751-x 15952058
28. Goetz MP Rae JM Suman VJ Safgren SL Ames MM Visscher DW Reynolds C Couch FJ Lingle WL Flockhart DA Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 2005, 23:9312-9318 10.1200/JCO.2005.03.3266 16361630
29. Tucker AN Tkaczuk KA Lewis LM Tomic D Lim CK Flaws JA Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients Cancer Lett 2005, 217:61-72 10.1016/ j.canlet.2004.08.027 15596297
30. Jin Y Desta Z Stearns V Ward B Ho H Lee KY Skaar T Storniolo AM Li L Araba A CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 2005, 97:30-39 15632378
31. Koch I Weil R Wolbold R Brockmöller J Husert E Burk O Nuessler A Neuhaus P Eichelbaum M Zanger U Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab Dispos 2002, 30:1108-1114 10.1124/dmd.30.10.1108 12228187
32. Shih PS Huang JD Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes Drug Metab Dispos 2002 30 1491 1496 10.1124/dmd.30.12.1491 12433824
33. Westlind-Johnsson A Malmebo S Johansson A Otter C Andersson TB Johansson I Edwards RJ Boobis AR Ingelman-Sundberg M Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism Drug Metab Dispos 2003, 31:755-761 10.1124/dmd.31.6.755 12756208
34. van Schaik RHN Cancer treatment and pharmacogenetics of cytochrome P450 enzymes Invest New Drugs 2005, 23:513-522 10.1007/s10637-005-4019-1 16267627
35. Nowell S Sweeney C Winters M Stone A Lang NP Hutchins LF Kadlubar FF Ambrosone CB Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy J Natl Cancer Inst 2002, 94:1635-1640 12419790
36. Lehmann D Nelsen J Ramanath V Newman N Duggan D Smith A Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition J Clin Pharmacol 2004, 44:861-865 10.1177/0091270004266618 15286089
37. Gallicchio L Tkaczuk K Lord G Danton M Lewis LM Lim CK Flaws JA Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer Cancer Lett 2004, 211:57-67 10.1016/ j.canlet.2004.04.001 15194217